📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 18:30
298 analysed today
FollowTelegram
298
Today
149,699
All-time analysed
42,924
Positive
6,662
Negative
91,432
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 Cons Loss Widens to ₹4.24 Cr; Revenue Declines 37.8% YoY to ₹15.30 Cr
ANG Lifesciences reported a 37.8% YoY drop in consolidated revenue from operations to ₹15.30 Cr for the quarter ended June 30, 2026, compared to ₹24.60 Cr in the corresponding prior-year period. Consolidated net loss widened significantly to ₹4.24 Cr against a net loss of ₹2.01 Cr in Q1 FY26. On a standalone basis, revenue dropped 43.1% YoY to ₹13.96 Cr with a net loss of ₹3.42 Cr. High finance costs of ₹2.24 Cr continue to severely strain operational performance against an existing debt load of ₹79 Cr.
Confidence: HIGH
What changedReported Q1 financial results showing sharp revenue contraction and widening quarterly net losses.
Why it mattersOperating scale continues to deteriorate while elevated finance costs outpace operational earnings, straining liquidity on a ₹79 Cr debt load.
Consolidated Revenue (Q1): ₹1,529.77 lakhsConsolidated Net Loss (Q1): ₹424.42 lakhsConsolidated Finance Costs (Q1): ₹223.51 lakhsStandalone Revenue (Q1): ₹1,395.79 lakhsConsolidated EPS (Q1): ₹(3.24)
📅 Short termLikely negative sentiment due to significant top-line de-growth and worsening net losses.
📈 Long termStructural challenges persist given high leverage (D/E 1.49) and negative operating cash generation.
⚠ Risk flags
- Persistent operational losses
- High debt burden relative to market cap and net worth
- Sharp drop in quarterly revenue
Key Highlights
Consolidated revenue from operations dropped 37.8% YoY to ₹1,529.77 lakhs (₹15.30 Cr)
Consolidated net loss widened to ₹424.42 lakhs (₹4.24 Cr) vs ₹200.62 lakhs loss in Q1 FY26
Standalone revenue fell to ₹1,395.79 lakhs with a net loss of ₹341.76 lakhs
Finance costs remained high at ₹223.51 lakhs for the quarter on a consolidated basis
Consolidated basic and diluted EPS declined to ₹(3.24) from ₹(1.52) YoY
👀 What to Watch
Track whether revenue can recover to historical run-rates in upcoming quarters and monitor any management commentary regarding debt servicing and cost rationalization.
ANG Lifesciences Q1 Revenue Down 38% YoY to ₹15.3 Cr; Net Loss Widens to ₹4.24 Cr
ANG Lifesciences reported consolidated revenue from operations of ₹15.30 crore for the quarter ended June 30, 2026, marking a 37.8% YoY decline from ₹24.60 crore in Q1 of the previous year. Consolidated net loss worsened substantially to ₹4.24 crore compared to a loss of ₹2.01 crore in Q1 FY26 and ₹1.38 crore in Q4 FY26. Standalone revenue fell 43.1% YoY to ₹13.96 crore with a standalone net loss of ₹3.42 crore. Persistent high finance costs of ₹2.24 crore continue to hurt operational margins amid a shrinking revenue base.
Confidence: HIGH
What changedANG Lifesciences reported its Q1 financial results showing a sharp drop in revenues and expanded operating and net losses.
Why it mattersTop-line contraction of nearly 38% YoY combined with widening net losses adds severe pressure on balance sheet leverage and debt-servicing capabilities.
Consolidated Revenue (Q1): ₹1,529.77 lakhsConsolidated Net Loss (Q1): ₹424.42 lakhsStandalone Revenue (Q1): ₹1,395.79 lakhsFinance Costs (Consolidated): ₹223.51 lakhsQ1 Revenue vs TTM Revenue: ~16.5%
📅 Short termSharp revenue contraction and worsening profitability are likely to maintain negative pressure on near-term sentiment.
📈 Long termTurnaround depends on demand recovery in pharma formulations and deleveraging to lower quarterly interest costs.
⚠ Risk flags
- Widening net losses
- High debt burden of ₹79 Cr (D/E of ~1.49)
- Sharp drop in top-line revenue
Key Highlights
Consolidated revenue from operations dropped 37.8% YoY to ₹1,529.77 lakhs (₹15.30 cr)
Consolidated net loss widened to ₹424.42 lakhs (₹4.24 cr) vs ₹200.62 lakhs in the year-ago period
Standalone revenue decreased to ₹1,395.79 lakhs with net loss at ₹341.76 lakhs
Consolidated finance costs remained high at ₹223.51 lakhs (₹2.24 cr) for the quarter
👀 What to Watch
Track whether management can arrest the top-line contraction in subsequent quarters and manage cash flows to service debt obligations (D/E of ~1.49).
